Compare Medpace Holdings Inc (MEDP) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Veritone Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Medpace Holdings Inc is far larger — about 282.9× Veritone Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Veritone Inc for 12 Days on average.
| MEDP | VERI | |
|---|---|---|
Market Cap | $16.82B | $59.46M |
Volume | 223,093 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $630.19 | $8.39 |
52-Week Low | $393.42 | $0.59 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | $16.44B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Veritone (VERI) trades at $0.58, down 16% today, reflecting ongoing investor concerns despite some positive business developments. The stock shows bearish technical signals with moving averages indicating strong selling pressure, while fundamentals reveal significant challenges with a -117.5% net income margin and consistent quarterly losses. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are offset by ongoing securities litigation investigations.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests substantial upside potential with a $3.75 price target. Key risks include the company's inability to achieve profitability, competitive pressures in AI solutions, and legal uncertainties. The stock presents high-risk speculation with potential for recovery if cost reductions and new partnerships drive meaningful revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
